secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001213900-22-013742
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix appoints Joseph Todisco as CEO effective by May 16, 2022
-----------------------------------------------------------------

- Joseph Todisco appointed CEO; expected start on or before May 16, 2022; will also join Board.
- Todisco previously EVP, Chief Commercial Officer at Amneal; 20+ years pharma experience.
- Employment agreement: $600k base salary, 65% target bonus, 500k stock options, 207k RSUs.
- Dr. Matt David to continue as Interim CEO/CFO until Todisco starts, then remain CFO.
- Company reaffirms focus on DefenCath NDA resubmission and commercial launch preparation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390022013742/0001213900-22-013742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390022013742/ea157150-8k_cormedixinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-013742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer